Local gene transfer of the human Lim mineralization protein (LMP), a novel intracellular positive regulator of the osteoblast differentiation program, can induce efficient bone formation in rodents. To develop a clinically relevant gene therapy approach to facilitate bone healing, we have used primary dermal fibroblasts transduced ex vivo with Ad.LMP-3 and seeded on a hydroxyapatite/collagen matrix prior to autologous implantation. Here, we demonstrate that genetically modified autologous dermal fibroblasts expressing Ad.LMP-3 are able to induce ectopic bone formation following implantation of the matrix into mouse triceps and paravertebral muscles. Moreover, implantation of the Ad.LMP-3-modified dermal fibroblasts into a rat mandibular bone critical size defect model results in efficient healing, as determined by X-rays, histology and three-dimensional microcomputed tomography (3DmCT). These results demonstrate the effectiveness of the non-secreted intracellular osteogenic factor LMP-3 in inducing bone formation in vivo. Moreover, the utilization of autologous dermal fibroblasts implanted on a biomaterial represents a promising approach for possible future clinical applications aimed at inducing new bone formation.
Introduction
Recombinant proteins, such as the bone morphogenetic proteins (BMP)-2 and -7 (also known as osteogenic protein 1), have been used to enhance repair of nonunion fractures and facilitate new bone formation in animal models as well as in clinical applications. However, a significant amount of recombinant BMP is required to promote osteogenesis, and frequently the extent of new bone formation is low. In contrast, local gene transfer of BMPs has been shown to be more efficient in promoting osteogenesis in rodents than the use of recombinant proteins. 1 Several different types of gene transfer techniques have been utilized for inducing bone formation in animal models of bone defects. Direct injection of viral vectors, such as adenovirus, adenoassociated virus and lentivirus, as well as implantation of plasmid DNA expressing BMPs or related osteogenic factors, have produced new bone in different models. 2 However, concerns about the immune response to the viral vectors and possible dissemination of the vectors have limited the clinical use of such approaches.
As an alternative to direct in vivo gene transfer, cell-based approaches, using cells genetically modified in culture to express an osteoinductive gene prior to implantation, have induced osteogenesis in different animal models. For the majority of these ex vivo approaches, multipotent stem cells, isolated from mesenchymederived adult tissues (bone marrow stroma, muscle, adipose tissue, and so on), expressing BMPs have been used successfully in different experimental models. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] In addition, differentiated cell types have also been reported to be effective for delivery of BMPs to induce bone formation in vivo. [16] [17] [18] [19] [20] [21] Bone morphogenetic proteins 2, 4, 8, 7 and 9 have all shown efficacy in facilitating bone formation in animal models. Similarly, gene transfer of intracellular proteins such as osterix (OSX) and Lim mineralization protein (LMP) have also been shown to induce osteogenesis in vivo. 22, 23 In particular, LMP was first identified as a gene induced by steroids in secondary fetal rat calvarial osteoblasts that contain LIM domains in the carboxyterminal half of the protein. 24 The human LMP gene is alternatively spliced to produce three isoforms, LMP-1, -2 and -3, with LMP-1 being the most similar to the rat LMP. Human LMP-1 and -3 have been shown to induce bone formation, whereas LMP-2 does not exert osteogenic properties following gene transfer, but instead may inhibit osteogenesis. 25, 26 The mechanism through which LMP induces osteogenesis is still poorly defined, but appears to be mediated through the activation of genes involved in osteogenesis, including runt-related transcription factor 2 (RunX2), OSX and certain BMPs. Thus, LMP seems to act as an upstream osteogenic factor. In addition, a region in LMP-1 and -3 has also been demonstrated to interact with the Smad ubiquitination regulatory factor 1, preventing ubiquitin-mediated degradation of the RunX2 and Smad proteins. 27 We have previously demonstrated that adenoviral gene transfer of human LMP-3 (Ad.hLMP-3) facilitates ectopic bone formation following direct injection as efficiently as BMP-2. 28 However, concerns about the dissemination of the adenoviral vector have prevented the clinical application of Ad.LMP-3 for facilitating healing of critical size bone defects. Thus, in this study, we have attempted to develop a clinically relevant approach for inducing bone formation using autologous fibroblasts isolated in primary culture from skin biopsies. Primary fibroblasts were transduced ex vivo to express LMP-3 and adsorbed onto a novel nanocomposite osteoconductive scaffold composed of 20% hydroxyapatite and 80% collagen (HA/COL). We demonstrated that this cell-based treatment facilitates highly efficient ectopic bone formation in mice and healing of a mandibular bone defect in rats. The efficient induction of osteogenesis by LMP-3-expressing fibroblasts clearly shows that intracellular LMP-3 is a potent osteoinductive agent. Moreover, given the limited invasiveness of the procedure for skin biopsy collection along with the easy isolation and in vitro expansion of dermal fibroblasts, this safe and effective approach could potentially lead to clinical applications.
Results

Adenovirus-mediated transduction efficiency in dermal fibroblasts
Dermal fibroblasts were isolated in primary culture from skin biopsies obtained from each mouse and each rat employed in this study (see Materials and methods). Cells were expanded in vitro and then infected with defective adenoviral vectors carrying either the LMP-3 gene (Ad.LMP-3) or the enhanced green fluorescent protein (Ad.eGFP) gene. To determine if primary dermal fibroblasts could be efficiently transduced with adenoviral vectors, cells were infected with Ad.eGFP using an MOI (multiplicity of infection) of 100 p.f.u. (plaqueforming units) per cell. eGFP-positive cells were then evaluated by fluorescence microscopy, which showed significant transgene expression at 24 h (Figure 1a ). The number of fluorescent cells approached 90% 48 h after transduction (Figure 1b) . Similar transduction efficiency, as measured by eGFP expression, was achieved in both murine-and rat-derived dermal fibroblasts (data not shown). In addition, cells were infected with Ad.LMP-3 (100 MOI) and transgene expression evaluated at different time points by means of reverse transcription-PCR (RT-PCR) and quantitative real-time PCR (qPCR), using sequence-specific primers for the LMP gene. Both analyses were performed in multiple experiments using RNA isolated from Ad.LMP-3-transduced cells at different time points. Ad.eGFP-transduced cells served as controls. Both RT-and real-time PCR showed efficient LMP-3 expression 24 and 48 h after infection with Ad.LMP-3 (Figures 1c and d) . Moreover qPCR demonstrated that the transgene expression in transduced cells slightly increased in a time-dependent manner up to Cells were harvested for mRNA isolation at specified time points after adenovirus-mediated transduction and transgene expression were examined by real-time PCR using sequence-specific primers. The b-actin gene was amplified by real-time PCR from the same RNA samples and used as a housekeeping control gene. Expression levels are expressed as fold change over the control, which was calculated according to the DDC t method as reported in the Materials and methods section.
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Matrix mineralization in vitro
We have previously demonstrated that LMP-3 transduction induces bone mineralization in vitro in both fibroblast and osteoblast cell lines. 28 Also dermal fibroblasts could not mineralize under basal conditions, but have the intrinsic potential to undergo mineralization on an efficient osteogenic stimulus. To assess the in vitro osteogenic potential of engineered dermal fibroblasts prior to in vivo implantation, we evaluated the formation of a mineralized matrix in Ad.LMP-3-transduced cells by Alizarin staining, using eGFP-transduced cells as a negative control. In vitro mineralization could be observed as early as 1 week after Ad.LMP-3 transduction, whereas no effect was observed in control cells (Figures 2a and b) . Similar results were obtained in three independent replicate experiments (see Supplementary file 1).
Delivery of engineered dermal fibroblasts using an osteoconductive scaffold in vivo
To evaluate whether transduction of the dermal fibroblasts with Ad.LMP-3 could result in in vivo bone formation, autologous dermal fibroblasts were isolated from each animal (mice and rats) and independently transduced ex vivo with Ad.LMP-3 prior to autologous implantation. Thus, autologous cells were used for implantation in recipient animals to mimic the clinical setting. To facilitate the delivery of cells, a nanocomposite osteoconductive scaffold comprised of HA/COL was prepared and seeded with Ad.LMP-3-transduced fibroblasts. Untransduced dermal fibroblasts seeded on the HA/COL scaffold and the unseeded scaffold were used as alternative negative controls. Figure 2 Intrinsic osteogenic potential in vitro of engineered dermal fibroblasts and persistence of transgene expression in vivo. Alizarin red staining was performed 1 week after cell infection aimed at evaluating the osteogenic potential in vitro of LMP-3-transduced dermal fibroblasts. The assay showed red-stained calcium deposits in LMP-3-transduced dermal fibroblasts (a), whereas no red-stained mineralized matrix could be demonstrated in the control eGFP-transduced cells (b). Fluorescence microscopy was used to assess whether transgene expression persisted in vivo over time after the implantation in fresh tissue sections: (c) rat mandibula treated with eGFP-transduced fibroblasts seeded on the HA/COL scaffold 1 month after surgery; (d) rat mandibula treated with unseeded biomaterial at the same time point. Scale bar, 10 mm in all panels. (Figures 2c and d) .
Ad.LMP-3 promotes efficient bone formation in vivo
The HA/COL scaffold seeded with engineered autologous dermal fibroblasts was implanted in recipient animals to evaluate the in vivo osteogenic potential of the LMP-3 cell construct. Naked scaffold and scaffold seeded with wild-type cells served as controls. For this purpose, we utilized three different experimental models: ectopic bone formation in mouse triceps and paravertebral muscles, along with a rat model of stable mandibular bone defect. The occurrence of bone formation at the site of implantation was then evaluated in time course by means of X-rays, histological analysis and microcomputed tomography (mCT), with three-dimensional (3D) reconstruction. None of the animals displayed evidence of systemic or local toxicity related to either the implantation procedure or the ex vivo gene delivery technique.
Ectopic bone models
Initially, the scaffold with seeded cells was inserted into mouse muscles, either into the triceps or the paravertebral muscle. The mice were then monitored for ectopic bone formation by X-ray and histology. In the group of mice receiving triceps implantation of the scaffold containing LMP-3-transduced cells, one out of five mouse was positive by X-rays and histology at 2 weeks. After 1 month, 6 out of 10 mice were positive by X-ray and histology, whereas 3 out of 5 were positive by both assays after 2 months (Figure 3 ; Table 1 ). Control animals, treated with either non-transduced cells or unseeded scaffold (HA/COL nanocomposite with sterile phosphate-buffered saline (PBS), were negative for bone formation at each time point tested. No significant differences among the control groups were detected (data not shown). Mice subjected to paravertebral implantation were positive for bone formation after 1 and 2 months, as determined by X-ray and histology, whereas the controls were negative for bone formation at both time points ( Figure 4 , Table 1 ). Moreover, all animals subjected to paravertebral implantation were examined by 3DmCT as well, which showed a large dense , mm 3 ) ¼ the sum of all voxels marked as bone inside the volume of interest; bone volume fraction (BV/TV, %) ¼ the ratio between BV and TV in percentage; bone thickness (BT, mm) ¼ mean thickness of bone trabeculae within the bone volume, derived from bone volume and bone surface density; degree of anisotropy (DA) ¼ corresponding to the preferential orientation(s) of trabeculae within the bone tissue. Based on these calculations, the newformed bone displayed characteristics similar to those of the vertebral bone ( Table 2 ). The 3DmCT analyses performed in control animals treated with eGFP-positive cells, non-transduced cells or unseeded HA/COL resulted negative, as no bone-like structure was evidenced at the site of implantation at each time point tested (Figures 5a, b and e). In particular, no bone-like structure could be observed as early as 1 month after surgery in animals subjected to unseeded scaffold implant (see Supplementary file 5). This result demonstrates that the naked osteoconductive scaffold does not have any osteogenic effect. Taken together, these results demonstrate that Ad.LMP-3 transduction of autologous dermal fibroblasts followed by implantation on a HA/COL scaffold results in efficient bone formation in two different ectopic bone formation models.
Rat mandibular bone defect
To determine if the proposed ex vivo approach can be considered a potential therapeutic tool in a relevant animal model of bone formation, a rat mandibular bone defect was used. In this model, a 5 Â 5 mm 2 full-thickness defect was created in the exposed mandible behind the root of the incisor without interrupting the bone continuity ( Figure 6a ). The defect was filled with the scaffold seeded with either LMP-3-transduced (group 1) or control cells (group 2) or with the naked scaffold (group 3). Four animals per group were killed at 4, 8 and 12 weeks, respectively, after surgical procedures for analyses of new bone formation by X-rays, histology and 3DmCT after killing. In all the animals, the entire regenerated mandible remained in its original position, without any sign of dislocation. All rats treated with autologous dermal fibroblasts transduced with Ad.LMP-3 showed positive X-rays and histology at 8 and 12 weeks after surgery, whereas only one out of four treated animals was positive as early as 4 weeks after surgery (Figures 6c, d , f, h and; Table 1 ). Neither radiological nor histological evidences of bone formation could be demonstrated in three out of four animals at the earliest time point (4 weeks) and in animals treated with scaffold alone or with non-transduced cells (Figures 6b, e, g, i and k). Also, there were no significant differences observed Abbreviation: mCT, microcomputed tomography. Number of positive radiological imaging (X-ray or CT) and histology assays obtained for animals subjected to LMP-3-transduced cell implantation and killed at the specified time points in the three experimental models. hLMP-3-expressing fibroblasts form new bone in vivo W Lattanzi et al among animals treated with either scaffold without cells or non-transduced fibroblasts at all time points (data not shown). The 3DmCT imaging studies revealed the successful repair of the defects implanted with LMP-3 cell constructs, which occurred in a time-related manner until 12 weeks after implantation (Figures 7b-d) .
Conversely, no bone formation was observed in the control group (Figure 7a) . To obtain quantitative data, the new bone surface area was calculated in each treated animal based on the measure of the mean diameter of the newly formed bone obtained from the CT lateral view of the rat skull (Figures 7e-h ). The mean area of the newly , indicating that about 75% of the hole produced in the mandible was filled with newly mineralized tissue 12 weeks after surgery.
Discussion
Existing techniques employing gene transfer for the delivery of osteogenic factors, such as BMPs and LMPs, have raised concerns about the inability to target the preferred site for induction of osteogenesis for in vivo applications. Thus, we have focused our efforts on developing a clinically relevant gene therapy approach, based on the use of autologous implantation of primary dermal fibroblasts for facilitating targeted bone formation in different types of animal models. The data presented here from in vitro experiments confirmed that dermal fibroblasts, easily and rapidly isolated in primary culture, can be efficiently transduced with adenoviral vectors. The potential plasticity of dermal fibroblasts has Table 2 for morphometric indexes calculated for the newly formed mass in treated animals.
hLMP 30 We have demonstrated that skin fibroblasts, which do not form bone under normal conditions, can undergo mineralization in vitro upon LMP-3 transduction, demonstrating their intrinsic osteogenic potential. However, we cannot exclude a role of other resident cells types, such as mesenchymal progenitors, in the osteogenic process in vivo, induced by factors released by the transduced fibroblasts. These results also demonstrate the effectiveness of the non-secreted, intracellular osteogenic factor, LMP-3, in inducing bone formation following delivery to autologous primary dermal fibroblasts in mice and rats. Specifically, the genetically modified autologous dermal fibroblasts were seeded on a biomaterial comprised of hydroxyapatite (HA) and collagen prior to implantation to target the site of desired new bone formation. We have previously demonstrated the exclusive bioconductive and resorption properties of the HA-based scaffolds, which were unable to form bone following naked implantation (unseeded biomaterial) in vivo and resulted in negative X-rays. 31 Here, we have demonstrated that transduction of the dermal fibroblasts with Ad.LMP-3 resulted in ectopic bone formation following implantation of the seeded scaffold into the mouse triceps and paravertebral muscles. Moreover, implantation of the scaffold seeded with Ad.LMP-3-modified dermal fibroblasts into a rat mandibular bone critical size defect model resulted in efficient healing. The rat mandibular fracture used in this study represents a clinically relevant model, as the defect is inherently stable over time, unable to repair autonomously. In addition, for all the animal models employed, autologous dermal fibroblasts were isolated from each animal to be treated to more accurately reflect the clinical setting. Thus, these results demonstrated that dermal fibroblasts transduced with defective adenoviral vectors efficiently deliver the osteogenic molecule promoting bone formation in vivo.
It has been demonstrated by others that BMPtransduced cells can induce bone in vivo. In particular, efficient ectopic bone formation and healing of bone defects were achieved following the implantation of skin fibroblasts expressing BMP-2 and -7.
18-21 However, in these ex vivo models, the osteoinductive potential did not seem to be related to the cell type, as BMPs are secreted and act as osteogenic molecules at the site of implantation. The type of vector used for gene delivery is more likely crucial to provide the correct level of transgenic protein for efficient osteoinduction. 19 The advantage of using LMP as the osteogenic agent is that it is a non-secreted protein, unlike BMP-2, thereby reducing any possible adverse effects due to high expression levels of an exogenous osteogenic factor. It has been demonstrated that LMP-3's osteoinductive properties are, at least in part, mediated through the upregulation of the BMP2 gene, being upstream to the main osteogenic pathways inside the cell. 28, 32, 33 Thus, the cell delivery of LMP-3 could possibly supply more physiologic levels of osteogenic molecules produced in vivo by genetically modified cells. Also, gene transfer offers certain advantages over the use of recombinant proteins such as BMP-2 and -7. The main limitation of using recombinant proteins for inducing bone formation in clinical applications is the need for delivery systems that provide a sustained, biologically appropriate concentration of the osteogenic factor at the site of the defect. Delivery needs to be sustained because these factors have exceedingly short biological half-lives, usually in the order of minutes or hours, rather than the days or weeks needed to stimulate a complete osteogenic response. Delivery also needs to be local to avoid ectopic ossification and other unwanted side effects. The use of local gene transfer offers great potential as a delivery system for osteogenic factors in that it meets the above requirements. Moreover, unlike recombinant proteins, the growth factor synthesized in situ as a result of cellbased gene transfer undergoes authentic post-translational processing and is presented to the surrounding tissues in a natural, cell-based manner. In fact, it has been reported that BMP-2 gene therapy produces a better response than recombinant BMP-2 protein in healing osseous defects in rats, although both approaches lead to osseous union. 1 The protocol described in this report represents a clinically relevant approach for facilitating new bone formation, as it is based on the use of autologous cells, which can be obtained from an extremely small skin biopsy and can be easily cultured ex vivo. Although adenoviral vectors are far from being adequate for gene therapy in the clinical setting, mainly due to the immune response, the use Ad.LMP-3 vector here provided a proof of the effectiveness of ex vivo gene delivery in this model. Alternative approaches to gene transfer, including the use of recombinant LMP-protein transduction domain fusion proteins and LMP-derived peptides, are currently being tested and hopefully will lead to future potential therapeutic applications.
The molecular mechanisms involved in LMP-induced osteogenesis are still unclear. LMP has been shown to induce the expression of BMPs, RunX2, OSX, bone sialoprotein, osteocalcin, osteopontin and alkaline phosphatase, although it is not clear whether its role in transcription modulation is direct or indirect. 28, 32, 33 A region of LMP has been shown to bind to and inhibit the activity of Smad ubiquitination regulatory factor 1, increasing the levels of RunX2 and Smad proteins. 27 However, there are additional regions of LMP-1 and -3 that are involved in osteogenesis. In fact, there appears to be at least three distinct regions in LMP-1 and -3 able to LMP-3 has been shown to induce certain osteogenic factors that are supposed to act in concert to induce osteogenesis in both undifferentiated and differentiated cell types, suggesting that it should be able to provide an optimal balance between osteogenic and inhibitory factors. As LMP-3 is capable of inducing the expression of osteogenic molecules, most of which are hLMP-3-expressing fibroblasts form new bone in vivo W Lattanzi et al secreted, it is likely that the osteogenic factors are released at physiologic levels in situ by LMP-3-engineered cells.
In conclusion, our data demonstrate that LMP-3 is a potent inducer of osteogenesis for in vivo applications and demonstrate the efficacy of a clinically relevant approach based on autologous transplantation of dermal fibroblasts.
Materials and methods
Construction of recombinant adenoviruses
E1-and E3-deleted adenoviral vector expressing human LMP-3 (Ad.hLMP-3) was constructed as previously described. 28 Briefly, the codon-optimized LMP-3 cDNA was subcloned into pcDNA3.1 TOPO T/A cloning plasmid (Invitrogen, Carlsbad, CA, USA). A SalI/NotI Figure 7 3DmCT analysis of the mandibular bone defect healing following treatment. 3D reconstructions of mCT scan images were obtained from rat mandibles after killing. (a) Control, mandible treated with unseeded scaffold at 8 weeks after surgery; (b) mandible treated with LMP-3-transduced cells seeded on the HA/COL after 4 weeks, (c) after 8 weeks and (d) after 12 weeks: the bone gap is partially filled with a CT dense tissue indicating local bone formation in rats 12 weeks after receiving the LMP-3 treatment. The lower panels show the empirical calculation methods of the surface areas. (e and f) Major diameters of the whole defect area and of the new-formed dense mass, respectively; (g and h) Minor diameters of the whole defect area and of the new-formed dense mass, respectively; all the four images are from the same animal. Surface areas were calculated in each animal based on the mean diameter measure and compared to the surface area of the defect to obtain a defect-filling ratio.
hLMP-3-expressing fibroblasts form new bone in vivo W Lattanzi et al fragment containing hLMP-3, derived from the plasmid pcDNA3.1/hLMP-3, was inserted in a modified version of the shuttle vector pAdlox (GenBank U62024). The adenoviral packaging cell line CRE8 was co-transfected with the SfiI-linearized shuttle plasmid of pAdlox/hLMP-3 and Ad.C5 helper virus DNA. Adenoviruses were then propagated on CRE8 cells, purified by cesium chloride density-gradient centrifugation and subsequent dialyzed according to standard protocols. An E1/E3-substituted recombinant adenovirus containing the cDNA for eGFP (Ad.eGFP) was used as the negative control.
Isolation and culture of autologous dermal fibroblasts
Cell culture media, sera, antibiotics, buffers, enzymes and supplements used for cell culture were all purchased from Lonza (Basel, Switzerland). Primary dermal fibroblast cultures were established using a 0.5 cm diameter punch biopsy of shaved skin obtained from the abdomen of each mouse and rat under general anesthesia and in aseptic conditions. The tissue was washed in sterile PBS, mashed into small fragments and left for 10 min in an incubator at 37 1C with 5% CO 2 and 85% humidity to enhance their adhesion to the plastic surface. Complete culture medium (Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 5% horse serum, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin) was then carefully added. Tissue cultures were incubated at 37 1C in a humidified incubator with 5% CO 2 until confluent fibroblast layers were obtained. Tissue fragments were then removed and cells were expanded in culture for at least six passages, plated at a density of 5 Â 10 4 cells cm
À2
and grown to 80% confluence for adenoviral infection.
Adenovirus-mediated transduction
Subconfluent dermal fibroblasts were infected with either Ad.LMP-3 or Ad.eGFP using an MOI of 100 p.f.u. per cell. Ad.eGFP was used as a vector control for testing transduction efficiency, whereas untransduced cells served as additional negative controls. The efficiency of adenovirus-mediated transduction was calculated by both evaluating the number of Ad.eGFP-transduced cells under fluorescence microscopy and measuring transgene expression in Ad.LMP-3-transduced cells by RT-PCR and qPCR, using LMP-3 sequence-specific primers. For animal treatments, transduced cells were harvested 24 h after viral infection, washed twice in PBS, resuspended in sterile PBS (2 Â 10 4 cells ml
À1
) and adsorbed onto a bone conductive composite (for detailed description see below).
RT-PCR. All reagents for molecular biology methods were purchased from Invitrogen unless otherwise specified. Expression of the transgenic hLMP-3 was assessed in transduced cells 24 and 48 h after infection. For this purpose, total RNA was isolated from treated and control untransduced cells using Trizol reagent, following the manufacturer's protocol, and digested with amplification grade DNase I, to remove genomic DNA traces in the sample, prior to RT. The yield from RNA isolation was determined using spectrophotometry (Beckman DU800; Beckman Coulter Inc., Fullerton, CA, USA) and the quality and integrity of total RNA were assessed by electrophoresis on 1% agarose gel in RNase-free conditions. A total of 1 mg of purified RNA was then reversetranscribed using SuperScript first-strand synthesis system with random hexamer primers, according to the manufacturer's suggested procedures. Finally, transgenic human LMP-3 sequence was amplified using the following sequence-specific oligonucleotides: hLMP-3_F, 5
0 -atggatagtttcaaggtc-3 0 ; hLMP-3_R, 5 0 -cagccacttgag gcgggc-3 0 . For comparative semiquantitative analysis of transgene expression, the b-actin gene was amplified in the tested samples and used as a housekeeping control. PCR was carried out in 50 ml volume, containing 2 ml of cDNA, 1 Â buffer, 1.5 mM MgCl 2 , 20 nM dNTPs, 1 mM of each primer and 1 U of Platinum Taq. Thermocycling conditions were as follows: initial denaturation and activation step at 95 1C for 2 min, followed by 30 cycles at 94 1C-58 1C-72 1C for 30 s each and then a final elongation step at 72 1C for 7 min. The PCR products were separated by electrophoresis on 2% agarose gel, stained with ethidium bromide and subjected to UV irradiation.
Real-time PCR. Transgenic LMP-3 expression was quantitatively assessed by real-time PCR on RNA isolated from dermal fibroblasts after 1, 2, 4, 7 and 14 days of adenovirus-mediated transduction, using Ad.eGFPtransduced cells at the same time points as negative controls. Three independent biological replicates for each tested time point were carried out. RNA was reversetranscribed as described above. To rule out genomic DNA contamination, no-reverse controls (that is, RT reactions carried out in the absence of the reversetranscriptase enzyme) were added for each sample. Thereafter, 1 ml of a 1:10 dilution of the single-stranded cDNA (corresponding to 20 ng) was used for real-time PCR, performed in a reaction volume of 20 ml using the SYBR green PCR master mix (Applied Biosystem, Foster City, CA, USA) and 1 mM of LMP sequence-specific primers. Target genes were normalized to the reference housekeeping 18S ribosomal RNA gene. The analysis was performed on an ABI Prism 7900 sequence detection system (Applied Biosystem). The PCR conditions were as follows: an initial incubation at 50 1C for 2 min and at 95 1C for 10 min, followed by 40 cycles at 94 1C for 15 s and at 60 1C for 1 min. Standard curves were generated for all the assays to verify PCR efficiency. The threshold cycle (C T ), which correlates inversely with the levels of target mRNA, was measured as the cycle number at which the reporter fluorescence emission exceeded a preset threshold level. The amplified transcripts were quantified using the comparative C T method as previously described, with the formula for relative fold change ¼ 2 ÀDDC T , where DDC T ¼ (DC T gene of interest (treated sample)ÀDC T 5S rRNA (treated sample))À(DC T gene of interest (control sample)ÀDC T 5S rRNA (control sample)), where DC T represents the mean C T value of each sample. 35 In vitro mineralization assay. Subconfluent dermal fibroblasts plated in six-well plates were infected with either Ad.LMP-3 or Ad.eGFP using an MOI of 100 p.f.u. per cell. The culture medium was changed 48 h after infection and cells were then incubated at 37 1C in a humidified incubator with 5% CO 2 for 14 days. Mineralization was assessed by Alizarin red staining 1 and 2 weeks after transduction. For this purpose, cells were fixed at the specified time points in 10% HA/COL nanocomposite preparation. The scaffold was assembled through a biomimetic synthesis based on the direct nucleation of HA into reconstituted collagen fibers during their assembling, as already described. 36 Briefly, phosphoric acid solution mixed with collagen suspension (1%) was added slowly to a Ca(OH) 2 aqueous solution. The crosslinking agent 1,4-butadienil diglicidil ether was then added to act as a crosslinking agent, stabilizing the polymer and reducing its solubility rate. During the crystallization process, the pH was maintained in the range 10-11 and the temperature at about 25 1C. The composites were air-dried and then freeze-dried, controlling the rate of the ice front propagation. The weight ratio of the HA/COL composite was 80:20. Total porosity was 85% with a mean macropore size of approximately 150 microns and a mean micropore size of approximately 5 microns. The estimated crystallite size along the c axis was approximately 12-15 nm. Compounds formed in this manner conform perfectly to natural bone tissue having a mineral phase with needleshaped morphology, nanometric dimensions and orientation of crystallites.
Animal models and surgical procedures. Three different ex vivo experimental models were used to assess the bone regenerative potential of the technique: two distinct models of ectopic bone formation in mouse and one experimental model of mandibular bone defect in rat. All procedures concerning animal use and care were conducted in accordance with the laboratory of Animal Care and Use Committee of the Catholic University of Rome. All animals were randomized into three groups based on the treatment received. The groups were as follows: group 1, autologous dermal fibroblasts transduced with Ad.LMP-3 and adsorbed onto the HA/COL; group 2, untransduced autologous dermal fibroblasts adsorbed onto the HA/COL scaffold; and group 3, HA/COL scaffold without cells, wetted with sterile PBS (previously referred to as naked or unseeded scaffold). Moreover, for each animal model, one animal per tested time point was treated with Ad.eGFP-transduced cells adsorbed onto the scaffold to assess the persistence of fluorescent cells over time. All surgical procedures were carried out under aseptic conditions. The animals were put into separate cages in temperature-controlled rooms, with a 12 h light-dark cycle, and had free access to commercial food and water. Accurate post-surgical controls were carried out for all animals by periodical monitoring of body weight, wound healing process at the surgical sites and functional recovery.
Mouse ectopic bone formation in the triceps muscle. Sixty 6-to 8-week-old male C57BL/6J mice were used in this protocol, assigned to protocol groups as follows: 20 each in groups 1, 2 and 3. Mice were anesthetized with a combination of 60 mg kg À1 ketamine and 6 mg kg À1 xylazine. A 0.5 Â 0.5 cm 2 pouch was created in the mouse triceps bilaterally through a linear incision of skin and subcutaneous tissues. The HA/COL composite was designed to be a 10 Â 10 mm 2 sphere on which the cell suspension was adsorbed. This cellscaffold compound was then carefully introduced into the muscle pouch. Unseeded scaffold, that is, HA/COL nanocomposite without cells, was used for negative controls, as described in the previous paragraph. Wounds were then closed by sewing with vicryl. After surgery, 5, 10 and 5 animals per group were killed for assessment of bone formation at 2 weeks, 1 month and 2 months, respectively.
Mouse ectopic bone formation in the paravertebral muscle. Six 6-to 8-week-old male C57BL/6J mice were assigned to each of the three experimental groups to be employed in this protocol. Mice were anesthetized as indicated above. The dorsal tract of the spine was reached using a posterior spine surgery approach. For this purpose, a 1 cm linear incision across the spinous processes was performed to expose the lamina bilaterally. In this case, the HA/COL composite was modeled to form a 1 cm long cylinder, which was wetted with the cell suspension or PBS alone. The scaffold was introduced bilaterally along the paravertebral muscles across the exposed spine tract. All tissues in the incision were then closed using vycril. Three mice per group were killed after 2 and 4 weeks, respectively, after surgery for detecting bone formation.
Rat mandibular defect. Thirty-six Wistar rats (250-300 g; Charles River Laboratories, Wilmington, MA, USA) were used for this surgical procedure using 12 animals for each experimental group. Rats were anesthetized with an intramuscular injection of a standard anesthetic cocktail consisting of ketamine hydrochloride (50 mg kg
) and xylazine (6 mg kg
). A linear incision was made along the inferior border of the mandible through the skin, subcutaneous tissues and masseter muscle, and then the medial and lateral surfaces of the horizontal arch of the mandible were exposed using an elevator. A 5 Â 5 mm 2 full-thickness defect was created in the exposed mandible behind the root of the incisor using a high-speed drill with irrigation, without interrupting the bone continuity. The resulting defect was filled with the cell-scaffold compound prepared as described previously. The incisions were finally closed using vicryl to sew muscle and covering skin. Four animals per group were killed 4, 8 and 12 weeks after surgical procedures by lethal injection of pentobarbital sodium 150 mg kg À1 intraperitoneally to detect the bone regeneration at the osteotomized sites.
mCT and 3DmCT. The mCT analysis was performed using a Skyscan 1072 microtomography apparatus (Skyscan, Kontich, Belgium) consisting of a microfocus X-ray source, a rotatable specimen holder and a detector system with a 1024 Â 1024 pixel size CCD camera. The scanning geometry was of the cone beam type. 37, 38 The X-ray projections were obtained as 12 bit gray level images and stored in a 16 bit file format. The scan settings used for mCT were 100 kVp, 98 mA, using 1 mm Al filter for beam hardening minimization, with 5.95 s exposure time and 0.451 rotation step. The magnification was set at Â 15, with a pixel size of 19 mm and with a 20 Â 20 mm 2 view field. The system was supplied with a 3.2 GHz Intel dual processor computer (1 Gbyte RAM).
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The cross-section reconstruction was performed using the CONE BEAM Reconstruction version 2.23 software (Skyscan) and the reconstructed tomographic images were stored in an 8 bit format (256 gray levels). The gray level images were segmented for the calculation of the bi-dimensional histomorphometric parameters, which served for the surface area calculation, using the CT Analyser software. A global threshold was used for the segmentation of the reconstructed images (software 3D CREATOR, version 2.4; Skyscan).
For the microtomographic imaging, a significant portion of the treated animal was dissected. In particular, all-length spine surrounded by the paravertebral muscles bilaterally was dissected and isolated for the mouse model of ectopic bone formation in the paravertebral muscle. For rats subjected to mandible treatment, the rat skull was isolated preserving muscles and soft tissues. For CT scanning and measurements, the fresh tissues were placed in an airtight cylindrical sample holder filled with formaldehyde to fix and preserve the sample for the duration of the measurement. The sample holders were marked outside with an axial line to obtain a consistent positioning of the specimens within the holder and to place them in the correct alignment on the mCT turntable. For all samples, a total of 482 microtomographic slices with a slice increment of 38 mm were acquired covering the total length of the sample. The following significant morphometric indexes were calculated for both the newformed mass and the vertebral bone in the paravertebral ectopic bone model, using the Skyscan implemented software: tissue volume (TV, mm 3 ) ¼ the total volume of interest in examination, represented by the sum of all voxels in a stack of slices (corresponding to the whole new-formed mass and to a section of bone of the vertebral body, respectively); bone volume (BV, mm 3 ) ¼ the sum of all voxels marked as bone inside the volume of interest; bone volume fraction (BV/TV, %) ¼ the ratio between BV and TV multiplied by 100 to obtain the value in percentage; bone thickness (BT, mm) ¼ mean thickness of bone trabeculae within the bone volume, derived from bone volume and bone surface density; degree of anisotropy (DA) ¼ this value corresponds to the preferential orientation(s) of trabeculae within the bone tissue. 29 The new-formed bone consisted mainly of cortical bone; therefore, the DA calculation was possible only for a restricted area of the analyzed volume.
Histology and morphological examination. Tissue specimens were dissected, embedded in Tissue-Tek O.C.T. compound (Bayer Healthcare, Newbury, UK) and frozen in liquid nitrogen. Frozen sections of 8 mm thickness were cut using a cryostat. Slides were fixed in 1% glutaraldehyde and stained using hematoxylineosin, von Kossa, toluidine blue and Alizarin red methods, following standard protocols to assess calcium deposits, matrix mineralization, cartilage and osteoid formation. Moreover, tissue sections obtained from animals treated with scaffold seeded with eGFP-positive cells were analyzed using fluorescence microscopy prior to the staining protocols, to assess the persistence of fluorescent cells and evaluate their effective adhesion and colonization of the scaffold.
